RedHill Biopharma Ltd. (NASDAQ: RDHL)

RedHill Biopharma Ltd., a prominent player in the specialty biopharmaceutical sector, operates primarily in the gastrointestinal (GI) and infectious diseases markets. The company is determined to establish itself as a leading specialty biopharmaceutical company, with a significant emphasis on the advancement of its development pipeline of clinical-stage therapeutic candidates.

RedHill's primary business activities revolve around the development and commercialization of therapeutic candidates for gastrointestinal and infectious diseases. The company's commercial operations are based in Raleigh, North Carolina, and it has a dedicated sales force to promote its products. RedHill Biopharma operates in various countries, including the United States, where it commercializes its primary products, Talicia and Aemcolo.

Talicia and Aemcolo are RedHill's primary revenue generators. Talicia is a new drug approved for the treatment of H. pylori infection in adults, while Aemcolo is an orally administered antibiotic approved for the treatment of travelers' diarrhea caused by non-invasive strains of E. coli in adults. Talicia, a proprietary new drug, combines omeprazole, amoxicillin, and rifabutin to address the high resistance of H. pylori bacteria to commonly used antibiotics in current standard-of-care therapies. Aemcolo, on the other hand, is a new chemical entity that employs MMX technology to deliver the antibiotic directly to the colon, avoiding unwanted effects on the beneficial bacterial flora in the upper portions of the gastrointestinal tract.

In the competitive landscape, Talicia faces competition from other branded prescription therapies indicated for H. pylori infection treatment, including Pylera and Voquezna, as well as generic versions of these drugs. However, RedHill believes that Talicia's efficacy, tolerability, and resistance profile give it a significant advantage over other marketed drugs. Aemcolo, too, faces competition from other prescription and over-the-counter anti-diarrheal medications, as well as from generic antibiotics such as fluoroquinolones and azithromycin. RedHill asserts that Aemcolo's ability to deliver the antibiotic directly to the colon sets it apart from other marketed drugs.

RedHill's therapeutic candidates include opaganib, RHB-107 (upamostat), RHB-104, RHB-102 (Bekinda), and RHB-204, most of which are in clinical development. Opaganib, a first-in-class, orally administered, sphingosine kinase-2 (SK2) selective inhibitor, exhibits anticancer, anti-inflammatory, and antiviral activities. It has been shown to inhibit the replication of positive-strand single-stranded ribonucleic acid (RNA) viruses, including SARS-CoV-2, demonstrating potential in treating severe COVID-19 pneumonia and cholangiocarcinoma.